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a b s t r a c t
Aging and inﬂammation are major contributing factors to the development and progression of arthritic
andmusculoskeletal diseases. “Inﬂammaging” refers to low-grade inﬂammation that occurs during phys-
iological aging. In this paper we review the published literature on cartilage aging and propose the term
“chondrosenescence” to deﬁne the age-dependent deterioration of chondrocyte function and how it
undermines cartilage function in osteoarthritis. We propose the concept that a small number of senes-
cent chondrocytes may be able to take advantage of the inﬂammatory tissue microenvironment and the
inﬂammaging and immunosenescence that is concurrently occurring in the arthritic joint, further con-
tributing to the age-related degradation of articular cartilage, subchondral bone, synovium and other
tissues. In this new framework “chondrosenescence” is intimately linked with inﬂammaging and the dis-
turbed interplay between autophagy and inﬂammasomes, thus contributing to the age-related increase
in the prevalence of osteoarthritis and a decrease in the efﬁcacy of articular cartilage repair. A better
understanding of the basic mechanisms underlying chondrosenescence and its modiﬁcation by drugs,
weight loss, improved nutrition and physical exercise could lead to the development of new therapeutic
and preventive strategies for osteoarthritis and a range of other age-related inﬂammatory joint diseases.
Aging is inevitable but age-related diseases may be modiﬁable.
© 2014 Published by Elsevier Ireland Ltd.
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1. IntroductionQ340
Aging is a natural and inevitable process by which living orga-Q441
nisms approach the twilight of their existence. Human aging is42
a complex physiological process, which is accompanied by the43
gradual decline and adaptation of different body systems to the44
unavoidablepassageof time. It is characterizedbyaprogressive loss45
of structure, function, co-ordination and physiological integrity,46
leading to impaired homeostasis in all systems [1]. Aging is a risk47
factor for a variety of chronic healthproblems including cancer, dia-48
betes, cardiovascular and neurodegenerative disorders. Advancing49
age is also a risk factor for arthritic and musculoskeletal diseases.50
There are common factors or “hallmarks” associated with each of51
these diseases. For example, there are six hallmarks associatedwith52
cancer (see [2,3]). Aging itself is characterized by nine hallmarks53
[1]. These include genomic instability, telomere attrition, epige-54
netic alterations, loss of proteostasis, deregulated nutrient sensing,55
mitochondrial dysfunction, cellular senescence, stem cell exhaus-56
tion, and altered intercellular communication. Current research is57
attempting to examine the relative contributions of the hallmarks58
of aging and the links between them in order to identify pathways59
and targets that can be exploited to promote healthy aging and60
develop new, more effective and more targeted drugs and treat-61
mentswithminimal sideeffects fordiseasesknowntobeassociated62
with aging (Fig. 1).Q563
Oneof thehallmarks of aging is cellular senescence.Normal cells64
possess a ﬁnite lifespan. Cells are continually exposed to a vari-65
ety of harmful exogenous and endogenous factors that may induce66
stress and cause reversible or irreversible damage leading to com-67
plete recovery or cell death, respectively [4]. Unlike cancer cells,68
normal cells do not divide indeﬁnitely due to a process known69
as cellular or replicative senescence [5]. Cellular senescence was70
formally described by Hayﬂick more than 50 years ago as a pro-71
cess that limited the growth and proliferation of normal human72
cells in culture [6]. Therefore, in cultured cells in vitro, replicative73
senescence limits the proliferation of normal cells, causing them to74
irreversibly arrest growth and adopt striking changes in cell form75
and function [7]. However, in vivo in aging adult tissues, senes-76
cent cells simply accumulatewithin tissues. Replicative senescence77
may contribute to ageing but it has been proposed that this pro-78
cess evolved to protect higher eukaryotes, particularly mammals,79
from developing cancer [8]. However, paradoxically, in older orga-80
nisms, senescent cellsmayhave theundesiredeffectof contributing81
to age-related pathologies and may actually contribute to car-82
cinogenesis [9]. Cellular senescence is an important mechanism83
for preventing the proliferation of potential cancer cells and it is84
increasingly recognized as a critical feature of mammalian cells85
to suppress tumorigenesis, acting alongside cell death programs86
[5,10].87
Mammalian organisms contain two types of cells: post-mitotic88
cells, which never divide, and mitotic cells, which have the capac-89
ity to divide. Examples of post-mitotic cells include nerve, muscle,90
and fat cells, most of which persist for life. Mitotic cells include91
epithelial and stromal cells of organs such as the skin. Post-mitotic92
and mitotic cells differ in their proliferative capacity, and thus93
they may age by different mechanisms [11]. Skin is an organ 94
that clearly shows the signs of aging. Senescent keratinocytes and 95
ﬁbroblasts accumulate with age in human skin. Senescent skin 96
cells possess a unique phenotype and exert long-range, pleiotropic 97
effects [11]. They express a distinctive set of degradative enzymes, 98
growth factors and pro-inﬂammatory cytokines [11]. Therefore, a 99
few senescent cells in tissues such as skin might be able to com- 100
promise its function and integrity. The same principle may apply to 101
several other tissues where a small number of senescent cells may 102
interfere with the physiological functions of that tissue. 103
In this paper we review the published literature that sup- 104
port the concept of “chondrocyte senescence” may have similar 105
effects in aging articular cartilage. We propose the term “chon- 106
drosenescence”, deﬁne it as the age-dependent deterioration of 107
chondrocytes and highlight its hallmarks and how they affect the 108
phenotype of these cells and their specialized functions. We also 109
propose theconcept that a small numberof senescent chondrocytes 110
may be able to take advantage of the inﬂammatory tissue microen- 111
vironment and the inﬂammaging and immunosenescence that is 112
concurrently occurring in the arthritis patient, further contributing 113
to the age-related degradation of articular cartilage and other joint 114
tissues. In this new framework chondrosenescence is intimately 115
linked with inﬂammaging and the disturbed interplay between 116
autophagy and inﬂammasomes [12]. This reﬁned deﬁnition con- 117
textualizes the pro-inﬂammatory phenotype of chondrosenescent 118
cells during the aging process and in age-related joint diseases, 119
implicating mitochondrial dysfunction [13,14], oxidative stress 120
and activation of inﬂammasomes [15]. The release of soluble and 121
insoluble factors secreted by senescent chondrocytes further con- 122
tributes to the inﬂammatory microenvironment that is believed 123
to drive the catabolic degradation of extracellular matrix (ECM) 124
macromolecules in articular cartilage. Since these molecules may 125
be viewed as biochemical markers (biomarkers) of chondrosenes- 126
cence,we also provide a brief overviewofmarkers thatmaybeused 127
to identify and characterize chondrocytes in vitro and in vivo. 128
2. Aging and inﬂammation—“Inﬂammaging” 129
“Inﬂammaging” is deﬁned as “low-grade chronic systemic 130
inﬂammation established during physiological aging” [16]. The 131
aging phenotype, is characterized by immunosenescence, and 132
is explained by an imbalance between inﬂammatory and anti- 133
inﬂammatory pathways, which results in a “low grade chronic 134
pro-inﬂammatory status” [17]. Inﬂammaging is thought to be driv- 135
ing force behind many forms of age-related pathologies, such as 136
neurodegeneration, atherosclerosis, metabolic syndrome, diabetes 137
mellitus and sarcopenia [16]. There is also increasing evidence 138
to suggest that inﬂammaging is also associated with inﬂamma- 139
tory diseases of the musculoskeletal system (i.e. osteoporosis, 140
osteoarthritis and rheumatoid arthritis) [18–20]. In this context, 141
humans and animals must maintain homeostasis as they age 142
despite incessant attack from both intrinsic and extrinsic stimuli 143
[21]. Increased longevity results in a reduced capacity to mount 144
inﬂammatory responses to infections and coordinate efﬁcient anti- 145
inﬂammatory responses to antigens and other noxious agents in 146
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Cellular Factors:
Apoptosis, secondary necrosis, hypocellularity
Mitochondrial and autophagic dysfunction
Catabolic factors:
Pro-inflammatory cytokines, chemokines, adipokines
Reactive oxygen species (ROS)
Nitric oxide (NO)
NF-κB
Prostaglandins, leukotrienes, bioactive lipids
Toll-like receptor (TLR)/Receptor for advanced 
glycation end products (RAGE) activation
Matrix metalloproteinases, aggrecanases, cathepsins 
Chondrosenescence: the age-
dependent deterioration of 
chondrocytes as a consequence of 
replicative (intrinsic) and stress-
induced (extrinsic) factors, resulting in 
the development of a “senescent 
secretory phenotype” 
Systemic and OA Risk Factors:
Age
Obesity, overweight and sedentary lifestyle
Mechanical factors
Joint trauma, joint instability, joint overuse, increased joint 
laxity - increased stiffness of periarticular ligaments and tendons
Anatomic factors, joint shape and conformation
Genetics, epigenetics
Metabolic disease
Diabetes mellitus – formation of advanced glycation 
end-products (AGEs), oxidative stress
Endocrine disease
Cellular Alterations:
Loss of phenotype and differentiated functions
Changes in chondrocyte metabolic activity
Increased sensitivity to pro-inflammatory and 
catabolic factors
Decreased responsiveness to anabolic growth 
factors
Impaired repair mechanisms
Development of a “senescent secretory phenotype” 
Joint Tissue Alterations:
Crepitus and cardinal signs of joint inflammation
Compromised tissue structure and function
Vascular invasion (angiogenesis), increased 
neurogenesis and altered nociception
Loss and degradation of extracellular matrix 
macromolecules
Consequent changes in subchondral bone and 
synovium
Musculoskeletal and CNS Factors:
Sarcopenia and muscle weakness
Loss of proprioception and balance
Synovial Factors: 
Synovitis
Related Musculoskeletal 
Conditions:
Osteoporosis?
Previous rheumatoid arthritis?
Previous septic arthritis?
Other musculoskeletal co-morbidities?
Bone Factors:
Bone marrow lesions
Systemic Alterations:
Chronic pain
Sleep disturbance
Increased disability
Loss of mobility
Increased morbidity
Adipose Tissue Factors: 
Increased adiposity
Fig. 1. The hallmarks of chondrosenescence. Chondrosenescence is deﬁned as the age-dependent deterioration of chondrocytes as a consequence of replicative (intrinsic) and
stress-induced (extrinsic) factors, resulting in the development of a “senescent secretory phenotype”. The intrinsic and extrinsic factors involved are listed.
our food and environment. Molecular evidence points to a dis-147
turbed interplay between autophagy and inﬂammasomes [12].148
Declined autophagic capacity in aging cells impairs the process149
of cellular housekeeping. This leads to protein aggregation, accu-150
mulation of misfolded proteins and the formation of dysfunctional151
mitochondria, which increases the generation of reactive oxygen152
species (ROS) thus promoting oxidative stress. Recent studies indi-153
cate that oxidative stress can induce the assembly of multiprotein154
inﬂammatory complexes called the inﬂammasomes [15]. Nod-like155
receptor protein 3 (NLRP3) is the major immune sensor for cellu-156
lar stress signals. NLRP3 inﬂammasome-dependent inﬂammatory157
responses are triggered by a variety of signals of host danger,158
including infection, tissue damage and metabolic dysregulation159
[13,14]. Inﬂammatory signals activate inﬂammasome-dependent160
responses and caspases, predominantly caspase-1, which cleaves161
the inactive precursors of interleukins, thus stimulating their ele-162
vated secretion and activity [12]. Consequently, these cytokines163
provoke inﬂammatory responses and accelerate the aging process164
by inhibiting autophagy, which is believed to be a protectivemech-165
anism in cartilage. Autophagy may be a protective or homeostatic166
mechanism in normal cartilage [22]. However, in OA it is associated167
with a reduction and loss ofUnc-51-like kinase 1 (ULK1), an inducer168
of autophagy, Beclin1, a regulator of autophagy, and microtubule-169
associated protein 1 light chain 3 (LC3), which executes autophagy170
and a increased chondrocyte apoptosis (see subsequent sections)171
[23].172
3. The inﬂammatory microenvironment of chondrocytes173
Chondrocytes exist in an avascularmicroenvironment,with low174
nutrient and oxygen levels [24,25]. Although chondrocytes rely175
on glycolysis [26], some of the metabolic functions of these cells176
are oxygen dependent [27,28]. Oxygen is mainly supplied by dif-177
fusion from the synovial ﬂuid [24,29]. Consequently, the lack of178
oxygen means that chondrocytes display a metabolism adapted to179
anaerobic conditions [27,28,30]. There is little published informa-180
tion about the regulation of antioxidant enzymes within cartilage.181
Equally little is known about the transport of antioxidants from 182
the circulation to chondrocytes. However, transport of nutrients, 183
oxygen and antioxidants to chondrocytes is thought to occur by 184
diffusion from subchondral bone [31] and the synovial microcir- 185
culation [32]. The role of subchondral bone in the pathogenesis of 186
cartilage damage has been underestimated [31]. There is increas- 187
ing evidence that vascular pathology plays a role in the initiation 188
and/or progression of OA [33]. In pathological conditions, oxygen 189
tension in synovial ﬂuid is subject to ﬂuctuation as blood ﬂow 190
may be reduced by venous occlusion and stasis, vascular shunt and 191
ﬁbrosis in synovium and/or by the development of microemboli 192
in the subchondral vessels [33]. In response to oxygen variations 193
induced through ischemia/reperfusion injury, mechanical stress, 194
immunomodulatory and inﬂammatory mediators, chondrocytes 195
produce abnormal levels of reactive oxygen species (ROS) that are 196
generally produced by immune cells [27,28,34]. The main ROS pro- 197
duced by chondrocytes are NO and superoxide anion that generate 198
derivative radicals, including peroxynitrite and hydrogen perox- 199
ide (H2O2) [35,36]. NO and its redox derivatives appear to have a 200
number of different functions in both normal and pathophysiolo- 201
gical joint conditions [37]. Low NO concentrations have protective 202
effects onother cell types and the literature that dealswith this area 203
is beyond the scope of this review. Chondrocytes stimulated with 204
pro-inﬂammatory cytokines produce large amounts of NO, which 205
hasbeen implicated inOAandhas the capacity to inhibit extracellu- 206
lar matrix production by interfering with important autocrine and 207
paracrine factors [38]. The published literature suggests important 208
roles for NO in inﬂammation and pain associated with OA but this 209
area is highly controversial andmoreworkneeds to be done to clar- 210
ify the role of NO in joint health and disease [39]. NO is synthesized 211
bynitricoxide synthase (NOS)enzymes.Chondrocytesexpressboth 212
endothelial (eNOS) and inducible (iNOS) forms of the enzyme. NO 213
production is stimulated by cytokines (i.e. IL-1, TNF-), interfer- 214
ons (i.e. interferon  (IFN-) and lipopolysaccharides (LPS). In fact 215
the increased expression of iNOS and cyclo-oxygenase-2 (COX-2) in 216
OA is largely due to the increased expression of pro-inﬂammatory 217
cytokines, particularly IL-1, which act in an autocrine/paracrine 218
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fashion to perpetuate a catabolic state that leads to progressive219
destruction of articular cartilage [40]. In contrast NO production is220
inhibited by growth factors such as transforming growth factor 221
(TGF-).222
In healthy cartilage chondrocytes possess robust defence mech-223
anisms against attack by NO, free radicals and reactive oxygen224
species (ROS). However, responses to ROS generation will be225
dependent on redox status at the cellular level and inﬂuenced by226
systemic levels of inﬂammatory mediators, if present. When the227
oxidant level does not exceed the reducing capacities of cells, ROS228
are strongly involved in the control of cellular functions including229
signal transduction. In contrast, in some pathological situations,230
when the cellular antioxidant capacity is insufﬁcient to detoxify231
ROS, oxidative stress may occur that degrade not only cellular232
membranes and nucleic acids but also extracellular components233
including proteoglycans and collagens. This is likely to happen in234
certain OA phenotypes. Furthermore, ROS can modify proteins by235
oxidation, nitrosylation, nitration or chlorination of speciﬁc amino236
acids, leading to impaired biological activity, changes in protein237
structure and accumulation of damaged proteins in the tissue.238
A further point that needs to be made in connection with oxida-239
tive stress is the fact that redox sensitive transcription factors240
(e.g. NF-B) are upregulated, which might result in an uncon-241
trolled inﬂammatory response. Oxidative stressmay also cause cell242
death and release of cellular content into extracellular environ-243
ment, activating clearance mechanisms in the microenvironment.244
Altogether, degradation products and cellular content containing245
oxidized molecules may contribute to the exacerbation of syno-246
vial inﬂammation and form a vicious circle, constituted by newly247
formed ROS and further degradation products.248
The enzyme complex NADPH, which catalyzes the reduc-249
tion of molecular oxygen to superoxide anion radicals, produces250
superoxide anion radicals. Biochemical studies have shown that251
chondrocytes express the large subunit of the ﬂavocytochrome252
of NADPH oxidase [41]. Even immortalized human chondrocyte-253
like cells lines express various components of the NADPH oxidase254
complex [42]. Articular chondrocytes also appear to express cell-255
speciﬁc components of NADPH oxidase complex such as p22phox,256
p40phox, p47phox, p67phox and gp91phox [41].257
4. Hallmarks of chondrosenescence258
There are common factors or “hallmarks” associated with every259
chronic disease. Six different hallmarks have been associated with260
cancer [2,3] and aging itself has at least nine hallmarks [1]. How-261
ever, there are no published papers that have speciﬁc hallmarks262
listed as being associated with chondrosenescent cells in OA. How-263
ever, beforewe list these hallmarks, it is appropriate to address this264
fundamental question: what is the impact of cartilage aging?265
Clearly, age is one of the most important risk factors for266
OA, followed by obesity, joint trauma, joint instability, genetic267
factors, underlying metabolic or endocrine disease. However, as268
we age, our tissues undergo age-related changes. These include269
changes in metabolic activity, mitotic activity, decreased sen-270
sitivity of chondrocytes to growth factors (especially changes271
in chondrocyte transforming growth factor  (TGF-) signalling272
[43]), decreased responsiveness to anabolicmechanical stimuli and273
impaired “repair mechanisms [44]. Age-related changes in articu-274
lar cartilage can contribute to the development and progression275
of OA. However, the degeneration of normal articular cartilage “is276
not simply the result of aging and mechanical wear” [45]. Nev-277
ertheless, aging modiﬁes the structure and function of articular278
cartilage and other joint tissues such as subchondral bone, mus-279
cle, soft tissues, synovial membrane, and synovial ﬂuid. In aging280
articular cartilage chondrocytes exhibit an age-related decline in281
proliferative and synthetic capacity while maintaining the abil- 282
ity to produce pro-inﬂammatory mediators and matrix degrading 283
enzymes [46]. These ﬁndings are characteristic of the senescent 284
secretory phenotype and are most likely a consequence of extrin- 285
sic stress-induced senescencedrivenbyoxidative stress rather than 286
intrinsic replicative senescence. Extracellular matrix changes with 287
aging also contribute to the propensity to develop OA and include 288
the accumulationof proteinsmodiﬁedbynon-enzymatic glycation. 289
5. The role of apoptosis in joint inﬂammation 290
Apoptosis, also known as programmed cell death (PCD) is 291
the physiologically regulated process of dell death that occurs in 292
multicellular organisms during embryonic development. Various 293
deﬁnitions have been proposed for apoptosis [47,48] since the term 294
was initially introduced by Kerr, Wyllie and Currie [49]. Research 295
carried out over the last twenty-ﬁve years has demonstrated a 296
clear role for apoptosis in a variety of chronic diseases including 297
joint inﬂammation andarthritis. Thedemonstrationofmacrophage 298
phagocytosis of aging neutrophils in joint inﬂammation was one 299
of the ﬁrst studies that linked apoptosis to arthritis [50]. Interest- 300
ingly, the authors of this original study proposed that apoptosis 301
in the synovial joint may represent a mechanism for the removal 302
of neutrophils during inﬂammation, a process that may serve to 303
limit the degree of joint injury during inﬂammation [50]. A few 304
years later apoptosis was observed in the synovium in rheumatoid 305
arthritis (RA) [51]. Firestein and colleagues studied RA synovial tis- 306
sue (ST) to determine if and where apoptosis occurs in situ. They 307
used immunohistochemical techniques to show that DNA strand 308
breaks occurmainly inmacrophages, although someﬁbroblast-like 309
cells in theRA synoviumwere also labelled. They alsoproposed that 310
pro-inﬂammatory cytokines regulate this process, and the cytokine 311
proﬁle in RA (high interleukin 1 (IL-1), high tumour necrosis 312
factor  (TNF-) and low interferon  (IFN-) along with local oxi- 313
dant injury might conspire to favour induction of apoptosis in the 314
synovium [51]. This was one of the ﬁrst reports of “inﬂammag- 315
ing” in the synovial joint, although this term was not speciﬁcally 316
mentioned at this stage. Further evidence for apoptosis in RA was 317
provided by ultrastructural studies that demonstrated Fas and Bcl- 318
2 expression in synovial ﬁbroblasts from patients with RA [52]. Fas 319
is an important cell surface receptor belonging to the TNF receptor 320
superfamily, alsoknownasCD95, that induces apoptosis onbinding 321
Fas ligand and Bcl-2 is an integral outer mitochondrial membrane 322
protein that blocks apoptosis and its increased abundance is a 323
reﬂection of apoptotic activity in tissues. Therefore, observations 324
of Fas antigen, Fas ligand and the tumour suppressor protein p53 325
over-expression in RA synovial tissue [53,54] and accumulation of 326
soluble Fas ligand in serum and synovial ﬂuid of patients with RA 327
[55] added further molecular evidence for the involvement of apo- 328
ptosis in joint inﬂammation and the accumulation of soluble Fas 329
in the joint cavity of RA patients was proposed as a mechanism 330
that may inhibit apoptosis and exacerbate the inﬂammatory pro- 331
cess [55]. The expression of Bcl-2 is thought to result in extended 332
life of matrix degrading synovial ﬁbroblasts at the site of synovial 333
invasion into cartilage and bone in RA joints [52]. Indeed, identi- 334
ﬁcation of apoptotic changes in osteocytes in pathological human 335
bone indicateda functional role for apoptosis in remodelling in joint 336
disease [56]. Increased synovial apoptosis and focally regulated 337
endothelial proliferation in the synovium pointed to microvascular 338
dysfunction as a mechanism for facilitating persistent synovitis in 339
RA [57]. 340
Transgenic mice lacking collagen II were found to exhibit 341
increased apoptosis and led to the suggestion that apoptosis may 342
also play a role in degenerative joint diseases such as OA in which 343
there is extensive cartilage loss [58]. Hashimoto et al., studied 344
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Fas/Fas ligand expression and induction of apoptosis in chon-345
drocytes from normal and OA cartilage [59]. They found that346
subpopulations of chondrocytes express Fas and are susceptible347
to Fas-induced apoptosis and Fas-mediated chondrocyte loss may348
contribute to cartilage degradation in OA [59] and RA [60]. Blanco349
et al., used FACS analysis and the TUNEL technique to show that350
OA chondrocytes indeed die by apoptosis and proposed increased351
apoptosis as a possible pathogenic pathway for OA [61]. Linking352
chondrocyte apoptosis and cartilage degradation in OA suggested353
that apoptosis and extracellular matrix depletion in articular car-354
tilage are anatomically linked and may be mechanistically related355
[62]. Taken together, these studies revealed that apoptotic chon-356
drocytedeathplays an important role in thepathogenesis ofOAand357
could be targeted for the development of new therapeutic strate-358
gies. Further mechanistic insight came from clinical and laboratory359
animal studies from the Lotz group in La Jolla that demonstrated360
a role for nitric oxide (NO) or antibody to Fas undergo cell death361
by apoptosis [63] (reviewed in [64]). Another elegant study by the362
Lotz group revealed that apoptotic bodies isolated fromNO-treated363
chondrocytes or cartilage contain alkaline phosphatase and NTP364
pyrophosphohydrolase activities and can precipitate calcium [65].365
This was the ﬁrst study that implicated chondrocyte-derived apop-366
totic bodies in the pathologic cartilage calciﬁcation seen in aging367
and OA.368
According to the recent literature there is a signiﬁcant decrease369
in chondrocyte abundance in articular cartilage with aging and a370
moderate to strong positive correlation exists between the degree371
of cartilage damage and chondrocyte death by apoptosis [66].372
Although there is a strength relation between chondrocyte apo-373
ptosis and cartilage degeneration in human osteoarthritis (OA), in374
40–60-year-old donors’ cartilages there are unusually high num-375
bers of apoptotic chondrocytes also in macroscopically normal376
cartilage [66].377
6. Morphological features of chondrocyte apoptosis378
Cells that undergo apoptosis exhibit a characteristic pattern of379
morphologic changes, including cell shrinkage, condensation, frag-380
mentation of the nucleus and bubbling of the plasma membrane,381
known as “blebbing,” and chromatin condensation and nucleoso-382
mal fragmentation [47]. These morphological features have been383
described in chondrocytes from murine models of OA [67] and in384
human OA samples [68]. Various methods have been published for385
evaluating them [69]. These features have also been described in386
hypertrophic chondrocytes in thegrowthplate [70]but the relevant387
literature is beyond the scope of this review. Some investigators388
have even proposed the term ‘chondroptosis’ to reﬂect the fact that389
chondrocytes may undergo apoptosis in a non-classical manner390
[71]. However, the term ‘chondroptosis’ has not been widely used391
or adopted. Freshly isolated chondrocytes fromhumanOAcartilage392
exhibit morphological evidence of apoptosis, with clear cytoplas-393
mic, cell-surface blebs, altered nuclear shape, apoptotic bodies and394
a parallel loss of nuclear volume [72].395
7. Targeting apoptotic pathways in OA396
Chondrocyte apoptosis is a challenging target for the develop-397
ment of therapeutic interventions for OA because of the potentially398
harmful systemic effects that pharmacological and biological399
regulators of apoptosismayhave, especially the potential for devel-400
opment of tumours. However, the joint is more isolated from401
systemic regulation than many other organs. Therefore, the death402
receptor, mitochondrial and endoplasmic reticulum pathways and403
the major cellular pathways that regulate apoptosis could be tar-404
gets of innovative new treatments. Of all the elements involved in405
the apoptosis of chondrocytes, caspase inhibition has been stud- 406
ied with the greatest detail (reviewed in [73]). However, caspases 407
are not the only targets. There are other molecular targets with 408
the capacity to modulate mitochondrial function and these have 409
already been reviewed [73]. 410
8. Age-related alterations in chondrocyte calcium 411
signalling pathways 412
Calcium signalling is extraordinarily diverse and versatile, 413
affecting almost all cellular functions including metabolism, 414
proliferation, differentiation, and apoptosis [74]. While calcium 415
homeostasis of differentiating and mature chondrocytes has been 416
partially characterized [75], little is known about age-related 417
changes of these pathways in senescent chondrocytes. It has long 418
been established that alterations in Ca2+ homeostasis, including 419
mitochondrial Ca2+ overload, are linked to aging [76]. For exam- 420
ple, in senescent detrusor as well as cerebral arterial smooth 421
muscle cells, calcium signals with decreased amplitudes but with 422
increased durations were observed, reﬂecting on disturbances in 423
both Ca2+ inﬂux (e.g. inhibition of voltage-operated calcium inﬂux, 424
increased calcium mobilization by ATP) and elimination pathways 425
[77,78]. This suggests that alterations in Ca2+ signalling can also 426
be expected in ageing chondrocytes. A recent study that evalu- 427
ated and compared gene expression proﬁles using microarrays in 428
knee joint tissues from younger and older adult mice after exper- 429
imentally induced OA, interesting alterations were found [79]. 430
Among the genes with altered expression in older mice compared 431
to younger animals, genes involved in Ca2+ signalling were signiﬁ- 432
cantly represented. The genes that were downregulated in older 433
mice included regulatory molecules: the histidine-rich calcium 434
binding protein (Hrc), which is a regulator of ER calcium sequestra- 435
tion, and the versatile intracellular regulatory protein S100B; the 436
ER calcium release channel RyR1; the alpha2/delta1 (CACNA2D1) 437
and gamma6 (CACNG6) regulatory subunits of voltage-gated cal- 438
cium channels; the sodium/calcium exchanger involved in calcium 439
elimination pathways (NCX3); and a calcium-regulated ion trans- 440
porter, the large conductance calcium-activatedpotassiumchannel 441
(KCa1.1; KCNMA1). At the same time, several other subsets of genes 442
involved in calcium homeostasis were found to be upregulated in 443
older mice vs. younger animals, including ionotropic purinergic 444
receptors P2X1, P2X4, P2X7, and the transient receptor potential 445
cation channel, subfamily C, members 1 and 6 (TRPC1, TRPC6). Dis- 446
turbed calciumhomeostasis in senescent chondrocytes is likely and 447
increased expression of purinergic receptors in aged chondrocytes, 448
similar to what has been observed in ageing myocytes, is of par- 449
ticular importance, considering the key role of these receptors in 450
the calcium homeostasis of chondrocytes [80,81]. It is therefore 451
clear that we are far from identifying biomarkers among the mem- 452
bers of the calcium toolkit that would be reasonable indicators for 453
chondrosenescence. However, the fact that there are alterations in 454
the mRNA expression of molecules involved in calcium signalling 455
implicates that research into this ﬁeld may shed more light on the 456
process of chondrosenescence. 457
9. Alterations in the chondrocyte channelome in aging 458
chondrocytes 459
Ion channels that enable ion transport across the plasma mem- 460
brane are vital components of cellular homeostasis. It is now 461
evident that chondrocytes are characterized by an ever-expanding 462
complement of ion channels referred to as the chondrocyte chan- 463
nelome [82]. The resting membrane potential (RMP), which is 464
known to control the mRNA expression of cartilage matrix com- 465
ponents [83] in chondrocytes, is maintained by plasma membrane 466
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ion transporters. Since altered activity of Na+ channels and ATP-467
sensitive K+ (KATP) channel has been reported in other tissues in468
various aging models [84,85], it is also realistic to expect age-469
related changes in the chondrocyte channelome. Indeed, changes470
have already been observed in KATP channel expression inOA chon-471
drocytes and the function of KATP channels appears to be impaired472
in OA chondrocytes [86] (see the following section for more473
details).474
In the previously mentioned microarray study that compared475
gene expression proﬁles in knee joint tissues from younger and476
older mice [79], alterations in the expression of genes encoding477
ion channels and other transporters were detected. Most impor-478
tantly, the2 isoform of the Na+, K+-ATPase (ATP1A2) was reported479
to be downregulated in aged cartilage. Apart from VOCC subunits480
and KCa1.1, other transporter subunits including NaVb4 voltage-481
gated sodium channel, or Na+/Ca2+ exchanger 3 (NCX3) were also482
downregulated. In contrast, several transporters were upregulated483
in aged cartilage vs. younger controls, for example the ligand-gated484
purinergic receptors P2X1, P2X4, P2X7, aswell as TRPC1 and TRPC6.485
Furthermore, the cation transporter ATPase type 13A2 (ATP13A2)486
was also found to be affected [79]. It is important to note that487
these data only show that there are alterations of these molecules488
at the mRNA expression level; however, there are no data avail-489
able regarding the protein level expression or function of these490
molecules.491
Therefore, it is only possible to consider these molecules as492
potential biomarkers of chondrosenescence when protein expres-493
sion and functional data become available.494
9.1. The role of mitochondrial dysfunction, anaerobic metabolism495
and oxidative stress in chondrosenescence496
Cellular senescence and mitochondrial dysfunction have both497
been listed among the nine tentative hallmarks of aging in different498
organisms [1]. In tissues where cells regularly replicate, gradual499
telomere shortening ultimately leads to deﬁnite arrest of cell cycle500
[87].501
In articular cartilage, where chondrocytes, the only resident502
cell type of the tissue are quiescent and rarely, if ever, divide503
under physiological conditions replicative senescence would seem504
unlikely. Nonetheless, telomere shortening was detected in chon-505
drocytes isolated from articular cartilage of older adults [88]. This506
“non-replicative” telomere erosion can be the result of various507
external and internal stressors such as continuous mechanical load508
or hypoxia. Articular chondrocytes are embedded into an avascu-509
lar extracellular matrix and supplied by oxygen and nutrients from510
synovial ﬂuid by slow diffusion. Although direct measurement of511
O2 tension in articular cartilage is difﬁcult, it does not exceed the512
O2 level of synovial ﬂuid, which has been estimated to be around513
5–6% [89]. Metabolism of articular chondrocytes is well adapted514
to this hypoxia and elevation of oxygen content of their environ-515
ment does not result in increased oxygen consumption [90]. The516
vital role of this unique oxygen homeostasis in development and517
maintenance of cartilage has been demonstrated by the observa-518
tion that hypoxia-inducible factor-1(HIF-1) was indispensable for519
survival of chondrocytes [91]; whether the expression level of HIF-520
1 changes with ageing of chondrocytes has not been elucidated521
yet. Hypoxia-induced genes include glucose transporters (GLUT1,522
GLUT3), which are important for anaerobic metabolism [25,92,93].523
Articular chondrocytes express multiple isoforms of these facilita-524
tive GLUTs and some have been shown to be regulated by growth525
factors and cytokines [25,93,94]. Although hypoxia, growth fac-526
tors and cytokines are involved in regulating the overall glucose527
transport capacity of human chondrocytes, recent studies have528
shown that ATP-sensitive potassium [K(ATP)] channels are present529
in chondrocytes [95] and are involved in the regulation of GLUT1530
and GLUT3 abundance in these cells. [86]. Therefore, K(ATP) chan- 531
nels are components of a broad glucose sensing apparatus that 532
modulates glucose transporters and allows chondrocytes to adjust 533
to varying extracellular glucose concentrations. However, the func- 534
tion of K(ATP) channels seems to be impaired in chondrocytes from 535
OA cartilage [86]. In addition, there is evidence for altered GLUT1 536
expression in OA chondrocytes and this may reﬂect a possible con- 537
tribution of altered glucose metabolism in the pathogenesis of this 538
disease [25,96]. One likely contributor to this scenario is altered 539
mitochondrialmetabolism inOA. Another contributing factor is the 540
lowdensity of chondrocyteswithin cartilage. Chondrocytes occupy 541
1–2% of the volume of the tissue in mature adult human articular 542
cartilage, which is approximately one tenth compared to that in 543
other tissues [97]. 544
10. Conclusions 545
The incidence of OA, the age-related inﬂammatory joint dis- 546
ease characterized by pain and loss of synovial tissue structure 547
and function due to articular cartilage degeneration, is steadily ris- 548
ing across the world as the aging population expands. Therefore 549
health and social care systems across the globe need to prepare 550
for a “tsunami” of OA cases in the next two decades. Although 551
there is a very strong association between age and increasing inci- 552
dence of OA, the disease itself is not an inevitable consequence of 553
aging; instead, aging increases the risk of OA. This is a very impor- 554
tant point and is often overlooked in the scientiﬁc literature. A 555
characteristic of OA is deviant behaviour of chondrocytes in dis- 556
eased articular cartilage [43]. OA chondrocytes resemble terminally 557
differentiated chondrocytes in the growth plate and actively pro- 558
duce pro-inﬂammatory cytokines and matrix degrading enzymes 559
[43,46]. These catabolic factors result in further cartilage degen- 560
eration. Progressive chondrocyte senescence is also characterized 561
by expression of senescence-associated markers, erosion of chon- 562
drocyte telomere length and mitochondrial dysfunction due to 563
oxidative damage causing the age related loss of chondrocyte func- 564
tion [98]. In appropriate joint loading and mechanical stresses 565
associatedwith abnormal loads on the joint considerably increased 566
the production of oxidants and soluble factors that sustain the 567
chondrosenescent phenotype [99]. Chondrosenescence and OA 568
are intimately linked and the premature senescence accounts 569
for age-related decline in chondrocyte function and indicate that 570
mechanically induced oxidative damage plays a role in this process 571
[99]. Poor cartilage repair in older patients is likely to be limited 572
by the inability of older chondrocytes to form new mechanically 573
competent cartilage. Chondrosenescence in vivo contributes to the 574
age-related increase in the prevalence of OA and decrease in the 575
efﬁcacy of cartilage repair [44]. Chondrosenescence directly affects 576
the extracellular matrix, resulting in a tissue that is functionally 577
impaired and less able to maintain homeostasis when stressed, 578
resulting in breakdown and loss of the articular cartilage, a clas- 579
sic hallmark of OA [46]. Age-related senescence and loss of muscle 580
and bone mass are also likely to be important as are sarcopenia 581
and increased bone turnover may also contribute to the develop- 582
ment of OA [100]. A better understanding of the basic mechanisms 583
underlying senescence and how the processmay bemodiﬁed could 584
provide novel approaches to slow the development of OA and lead 585
to the development of new therapeutic strategies that may delay 586
the onset of chondrocyte senescence or replace senescent cells 587
[101]. 588
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